Vaccines for pandemic influenza: Summary of recent clinical trials

Current Topics in Microbiology and Immunology

Volumn 333, Issue 1, 2009, Pages 431-451

  Keitel, Wendy A ^a   Atmar, Robert L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS A H2N2 VACCINE; INFLUENZA VIRUS A H5N1 VACCINE; INFLUENZA VIRUS A H7N7 VACCINE; INFLUENZA VIRUS A H9N2 VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; LIVE VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS SIALIDASE;

ANTIBODY RESPONSE; CLINICAL TRIAL; CROSS REACTION; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG SAFETY; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VIRUS A H2N2; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N7; INFLUENZA VIRUS A H9N2; LOW DRUG DOSE; PANDEMIC INFLUENZA; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE;

EID: 73949107102     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-92165-3_21     Document Type: Review

References (76)

1. Antonovics J, Hood M, Baker C. (2006) Molecular virology: was the 1918 flu avian in origin. Nature 440(7088):E9-E10
2. Atmar RL, Keitel WA, Patel SM, Katz JM, She DW, El Sahly H, Pompey J, Cate TR, Couch RB. (2006) Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 43:1135-1142
3. Bean WJ, Schell M, Katz J et al. (1992) Evolution of the H3 influenza virus hemagglutinin from human and nonhuman hosts. J Virol 66:1129-1138
4. Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, Van Hoecke C, Howe BJ, Dubin G. (2004) Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 351:2286-2294
5. Belshe RB, Newman FK, Wilkins K, Graham IL, Babusis E, Ewell M, Frey SE. (2007) Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 25:6755-6763
6. Bernstein D, Edwards K, Dekker C, Belshe R, Talbot H, Graham I, Noah D, He F, Hill H. (2008) Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 197:667-675
7. Brady RC, Treanor JJ, Atmar RL, Chen WH, Winokur P, Belshe R. (2007) A phase I-II, randomized, controlled, dose-ranging study of the safety, reactogenicity, and immunogenicity of intramuscular inactivated influenza A/H5N1 vaccine given alone or with aluminum hydroxide to healthy elderly adults. Abstract P739 of the Options for the Control of Influenza VI Meeting, Toronto, ON, Canada, 17-23 June 2007
8. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Höschler K, Zambon MC. (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367:1657-1664
9. Campbell J, Graham I, Zangwill K. (2007) Pediatric H5N1 vaccine trial (online slideshow). http:// www.who.int/vaccine-research/diseases/influenza/ 150207-Campbell.pdf
10. Chen H, Smith GJ, Li KS et al. (2006) Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci USA 103:2845-2850
11. Committee for Human Medicinal Products (CHMP) (2007) Influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context. CHMP/VWP/263499/06, 1-11
12. Cunha B. (2004) Influenza: historical aspects of epidemics and pandemics. Infect Dis Clin North Am 18(1):141-55
13. Desheva JA, Lu XH, Rekstin AR, Rudenko LG, Swayne DE, Cox NJ, Katz JM, Klimov AI. (2006) Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Vaccine 24:6859-6866
14. Ehrlich H, Muller M, Oh H, Tambyah P, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Low-Baselli A, Vartian N, Bobrovsky R, Pavlova B, Pollabauer E, Kistner O, Barrett P (2008) for the Baxter H5N1 pandemic influenza vaccine clinical study team. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358:24:2573-2584
15. Ernst WA, Kim HJ, Tumpey TM, Jansen ADA, Tai W, Cramer DV, Adler-Moore JP, Fujii G. (2006) Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 24:5158-5168
16. Food and Drug Administration. (2006) Draft guidance for industry on clinical data needed to support the licensure of trivalent inactivated influenza vaccines. Fed Reg 71:12367
17. Gibbs M, Gibbs A. (2006) Molecular virology: was the 1918 pandemic caused by bird flu. Nature 440:27:E8
18. Glezen PW. (1996) Emerging infections: pandemic influenza. Epidemiol Rev 18:64-76
19. Goji N, Nolan C, Hill H, Wolff M, Noah D, Williams T, Rowe T, Treanor J. (2008) Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/ Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis 198:9: 635-641
20. Govorkova EA, Webby R, Humberd J, Seiler JP, Webster RG. (2006) Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterolo-gous challenge. J Infect Dis 194:159-167
21. Guan Y, Poon LL, Cheung CY et al. (2004) H5N1 influenza: a protean pandemic threat. Proc Natl Acad Sci USA 101, 8156-8161
22. Hampson A. (2006) Ferrets and the challenges of H5N1 vaccine formulation. J Infect Dis 194:143-145
23. Hanson BJ, Boon ACM, Lim APC, Webb A, Ooi EE, Webby RJ. (2006) Passive immunoprophy-laxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemag-glutinin in mice. Respir Res 7:126
24. Hehme N, Engelmann H, Kunzel W, Neumeier, Sanger R. (2002) Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol 191:203-208
25. Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. (2004) Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 103:16-171
26. Hoelscher MA, Garg S, Bangari DS et al. (2006) Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367:475-481
27. Karron R, Callahan K, Luke C et al. (2007) Phase I evaluation of live attenuated H9N2 and H5N1 ca reassortant vaccines in healthy adults (online slideshow). http://www.who.int/vaccine-research/diseases/influenza/160207- Karron.pdf Karron R et al. (2008) Clinical evaluation of live attentuated pandemic influenza virus vaccines (online slideshow). http://www.who.int/ vaccine-research/diseases/influenza/Karron-infleunza-meeting-140208.pdf
28. Karron RA, Callahan K, Luke C, Thumar B, McAuliffe J, Schappell E, Joseph T, Coelingh K, Jin H, Kemble G, Murphy BR, Subbarao K. (2009) A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J Infect Dis 199:711-16
29. Keitel W, Campbell J, Treanor J, Walter E, Patel S, He F, Noah D, Hill H. (2008) Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: Results of a phase-I-II randomized clinical trial. J Infect Dis 198:11:1309-1315
30. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. (2004) Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351:2295-2301
31. Kistner O. (2007) Phase 1/2 clinical study with Baxter's H5N1 vaccine: clinical update (online slide-show). http://www.who.int/vaccine-research/ diseases/influenza/150207-Kistner-Baxter.pdf
32. Kodihalli S, Goto H, Kobasa DL, Krauss S, Kawaoka Y, Webster RG. (1999) DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J Virol 73:2094-2098
33. Koopmans M, Wilbrink B, Conyn M, Natrop G, Van Der Nat H, Vennema H, Meijer A, Van Steenbergen J, Fouchier R, Osterhaus A, Bosman A. (2004) Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 363:587-593
34. Krasilnikov I. (2008) MICROGEN's pandemic vaccine clinical development (online slideshow). http://www.who.int/vaccine-research/diseases/influenza/ Krasilnokov-infleunza-meeting- 140208.pdf
35. Laddy DJ, Yan J, Corbitt N, Kobasa D, Kobinger GP, Weiner DB. (2007) Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 25:2984-2989
36. Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn A-D, Vandermeulen C, Forgus S, Leroux-Roels G, Pichon S, Kusters I. (2008) An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 198:9:642-649
37. Leroux-Roels, Barkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, Devaster JM, Leroux-RoelsG. (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomized controlled trial. Lancet 370:580-589
38. Leroux-Roels I, Bernhard R, Gérard P, Dramé M, Hanon E, Leroux-Roels G. (2008) Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 3(2):e1665
39. Lin YP, Shaw M, Gregory V et al. (2000) Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proc Natl Acad. Sci USA 97:9654-9658
40. Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z, Yang M, Sun R, Li C, Lin S, Ji M, Liu Y, Wang X, Wood J, Feng Z, Wang Y, Yin W. (2006) Safety and immu-nogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368, 991-997
41. Lipatov AS, Webby RJ, Govorkova EA, Krauss S, Webster RG. (2005) Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model. J Infect Dis 191:1216-1220
42. Lipatov AS, Hoffman E, Salomon R, Yen HL, Webster RG. (2006) Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/ Vietnam/1203/04(H5N1) virus in ferrets. J Infect Dis 194:1040-1043
43. Lu J, Guo Z, Pan X, Wang G, Zhang D, Li Y, Tan B, Ouyang L, Yu X. (2006a) Passive immuno-therapy for influenza A/H5N1 virus infection with equine hyperimmune globulin F (ab¢)2 in mice. Respir Res 7:43
44. Lu X, Edwards LE, Desheva JA, Nguyen DC, Rekstin A, Stephenson I, Szretter K, Cox NJ, Rudenko LG, Klimov A, Katz JM. (2006b) Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 24:6588-6593
45. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. (2006) Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment. Ann Intern Med 145:599-609
46. Ma W, Vincent A, Gramer M, Brockwell C, Lager K, Janke B, Gauger P, Patnayak D, Webby R, Richt J. (2007) Identification of H2N3 influenza A viruses from swine in the United States. Proc Natl Acad Sci USA 104:52:20949-20954
47. Maassab HF, DeBorde DC. (1985) Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine 3:355-69
48. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, Hughes M, Perez DR, Donis R, Hoffmann E, Hobom G, Kawaoka Y. (1999) Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci USA 96:9345-9350
49. Nicholson KG, Colgate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC. (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/ Singapore/97 (H5N3): a randomized trial of two potential vaccines against H5N1 influenza. Lancet 357:1937-1943
50. Nolan T, Richmond P, Skeljo M, Pearce G, Hartel G, Formica N, Hoschler K, Bennet J, Ryan D, Papanaoum K, Basser R, Zambon M. (2008a) Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 26:4160-4167.
51. Nolan T, Richmond P, Skeljo M et al. (2008b) Prototype H5N1 pandemic influenza vaccine: further studies on elderly and children (online slideshow). http://www.who.int/vaccine-research/diseases/influenza/Nolan-infleunza-meeting- 140208.pdf
52. Nolan T, Richmond P, Formica N, Hoschler K, Skeljo M, Stoney T, McVernon J, Hartel G, Sawlwin D, Bennet J, Ryan D, Basser R, Zambon M. (2008c) Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 26:6383-91.
53. Patel SM, Atmar RL, El Sahly H, Cate TR, Keitel WA . (2006) A randomized, open-label, phase I clinical trial comparing the safety, reactogenicity, and immunogenicity of booster immunization with inactivated influenza A/H5N1 vaccine administered by the intradermal (ID) or the intramuscular (IM) route among healthy adults. In: 44th Annual Meeting of the Infectious Diseases Society of America, Toronto, ON, Canada, 12-15 Oct 2006
54. Patel SM, Atmar RL, El Sahly H, Cate TR, Keitel WA . (2008) A phase I/II, randomized, double-blinded placebo-controlled trial to assess the safety, reactogenicity, and immunogenicity of immunization with inactivated subvirion influenza A/H5N1 vaccine administered by the intra-dermal or the intramuscular route among healthy adults. Abstract S1 of the 11th Annual Conf on Vaccine Research, Baltimore, MD, 5-7 May 2008
55. Ruat C, Caillet C, Bidaut A, Simon J, Osterhaus A. (2008) Vaccination of macaques with adju-vanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement. J Virol 82:2565-69
56. Rudenko L, Katlinsky A. (2007) Evaluation of Russian live evaluation of Russian live attenuated vaccine H5N2 attenuated vaccine H5N2 in clinical trials (online slideshow). http://www.who. int/vaccine-research/diseases/influenza/ 160207-Rudenko.pdf
57. Rümke HC, Bayas JM, De Juanes JR, Caso C, Richardus JH, Campins M, Rombo L, Duval X, Romanenko V, Schwarz TF, Fassakhov R, Abad-Santos F, Von Sonnenburg F, Dramé M, Sänger R, Ballou WR. (2008) Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 26(19):2378-2388. doi:10.1016/j.vaccine.2008.02.068
58. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. (2006) Influenza virus receptors in the human airway. Nature 440:435-436
59. Stephenson I, Nicholson KG, Colegate A, Podda A, Wood J, Ypma E, Zambon M. (2003a) Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 21:1687-1693
60. Stephenson I, Nicholson KG, Glück R, Mischler R, Newman RW, Palache AM, Verlander NQ, Warburton F, Wood JM, Zambon MC. (2003b) Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomized trial. Lancet 362:1959-1966
61. Stephenson I, Wood JM, Nicholson KG, Zambon MC. (2003c) Sialic acid receptor specificity on eryth-rocytes affects detection of antibody to avian influenza haemagglutinin. J Med Virol 70:391-398
62. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. (2004) Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 103:91-95
63. Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood JM, Zambon MC, Katz JM. (2005) Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 191:1210-1215
64. Stephenson I, Das RG, Wood JM, Katz JM. (2007) Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 25:4056
65. Suguitan AL Jr, McAuliffe J, Mills KL, Jin H, Duke G, Lu B, Luke CJ, Murphy B, Swayne DE, Kemble G, Subbarao K. (2006) Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 3:e360
66. Tashiro M. (2007) Development of pandemic vaccine in Japan: P I and P II/III clinical studies (online slideshow). http://www.who.int/vaccine-research/ diseases/influenza/150207-Tashiro.pdf
67. Taubenberger J, Reid A, Lourens R, Wang R, Guozhong J, Fanning T. (2005) Characterization of the 1918 influenza virus polymerase genes. Nature 437:889-893
68. Treanor JJ, Wilkinson BE, Masseoud F et al. (2001) Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19:1732-1737
69. Treanor JJ, Campbell James D, Zangwill KM, Rowe T, Wolff M. (2006) Safety and immunogenic-ity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354:1343-1351
70. Treanor J, Bernstein D, Edwards K, Zangwill K, Noah D. (2007) Evaluation of inactivated monova-lent rga/Vietnam/1203/04 X PR8 subvirion vaccine in healthy elderly adults. Abstract P731 of the Options for the Control of Influenza VI Meeting, Toronto, ON, Canada, 17-23 June 2007
71. Vajo Z, Kosa L, IIdiko V, Jankovics M, Jankovics I. (2007) Inactivated whole virus influenza A (H5N1) vaccine. Emerg Infect Dis 13(5):807-808
72. Watanabe T, Watanabe S, Kim J, Hatta M, Kawaoka Y. (2008) Novel approach to the development of effective H5N1 influenza a virus vaccines: use of M2 cytoplasmic tail mutants. J Virol 82:5:2486-2492
73. Wright PF, Thompson J, Vaughn WK, Folland DS, Sell SHW, Karzon DT. (1977) Trials of influenza A/New Jersey/76 virus-vaccine in normal children: overview of age-related antigenicity and reactogenicity. J Infect Dis 136:S731-S741
74. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A. (H5N1) Virus (2008) Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 358:261-273
75. Zangwill K, Treanor JJ, Campbell JD, Noah DL, Ryea J. (2008) Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis 197:580-583
76. Zhou B, Zhong N, Guan Y. (2007) Treatment with convalescent plasma for influenza A(H5N1) infection. N Engl J Med 357:1450